Edwards Lifesciences EW Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.3B+14.1% | $6.07B+11.5% | $5.88B+10.6% | $5.69B+9.1% | $5.52B+7.9% | ||
| $1.4B+23.2% | $1.33B+19.4% | $1.28B+19.2% | $1.2B+12.9% | $1.13B+8.3% | ||
| $4.91B+11.8% | $4.73B+9.5% | $4.6B+8.4% | $4.48B+8.2% | $4.39B+7.8% | ||
| 77.9%-1.6pp | 78%-1.4pp | 78.2%-1.6pp | 78.9%-0.7pp | 79.5%-0.1pp | ||
| $1.09B+3.5% | $1.08B+2.5% | $1.08B+5.7% | $1.06B+4.1% | $1.05B+6.7% | ||
| $2.14B+17.3% | $2.09B+16.5% | $1.97B+15.2% | $1.88B+12.3% | $1.83B+11.6% | ||
| $62.3M+221% | $67.2M+22,300% | $75.6M+438% | $40.7M— | $19.4M— | ||
| $1.35B-5.4% | $1.26B-8.3% | $1.43B+0.9% | $1.47B+2.9% | $1.42B+7.5% | ||
| 21.4%-4.4pp | 20.8%-4.5pp | 24.2%-2.3pp | 25.8%-1.6pp | 25.8%-0.1pp | ||
| —— | —— | —— | —— | $126.73M+57.5% | ||
| $1.3B-19.4% | $1.27B-17.8% | $1.57B+3.1% | $1.63B+7.7% | $1.61B+15.0% | ||
| $224.9M+27.7% | $216.9M+42.6% | $235.8M+67.1% | $220.4M+44.0% | $176.1M+14.4% | ||
| $1.1B-73.8% | $1.07B-74.3% | $1.37B-67.1% | $4.15B+182% | $4.18B+196% | ||
| 17.4%-58.3pp | 17.7%-59.1pp | 23.2%-54.9pp | 73%+44.7pp | 75.7%+48.1pp | ||
| $20.6M-99.2% | $13.4M-99.5% | $25.7M-99.1% | $2.74B+2,331% | $2.74B+1,555% | ||
| $1.88-73.1% | $1.83-73.7% | $2.32-66.5% | $6.95+186% | $7.00+202% | ||
| $1.89-73.0% | $1.84-73.6% | $2.33-66.4% | $6.97+187% | $7.01+201% | ||
| 2.3B-2.1% | 2.3B-2.4% | 2.4B-2.3% | 2.4B-2.2% | 2.4B-1.8% | ||
| 2.3B-2.0% | 2.3B-2.3% | 2.4B-2.1% | 2.4B-2.0% | 2.4B-1.6% | ||
| $1.85-23.6% | $1.81-22.6% | $2.28-1.3% | $2.39+6.2% | $2.42+17.5% | ||
| $1.84-24.0% | $1.80-23.1% | $2.27-1.7% | $2.38+5.8% | $2.42+18.0% | ||
| $0.04-99.1% | $0.03-99.4% | $0.05-98.9% | $4.57+2,439% | $4.58+1,596% | ||
| $351.6M+729% | $325.4M+705% | $129.4M+243% | $49.8M+71.1% | $42.4M-74.9% | ||
| $76.1M+15.7% | $7.2M-89.6% | $37.3M-4.8% | $62.5M+249% | $65.8M+258% | ||
| $62.3M+221% | $67.2M+22,300% | $75.6M+438% | $40.7M— | $19.4M— | ||
| —— | $19.1M-68.7% | $29.58M-35.4% | $40.05M+31.3% | $50.53M+231% | ||
| —— | —— | —— | —— | —— | ||
| $6.3B+14.1% | $6.07B+11.5% | $5.88B+10.6% | $5.69B+9.1% | $5.52B+7.9% | ||
| $1.51B-4.4% | $1.42B-7.4% | $1.58B+1.3% | $1.62B+2.6% | $1.58B+7.1% | ||
| 23.9%-4.6pp | 23.4%-4.8pp | 26.9%-2.5pp | 28.5%-1.8pp | 28.6%-0.2pp | ||
| $1.35B-5.4% | $1.26B-8.3% | $1.43B+0.9% | $1.47B+2.9% | $1.42B+7.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Edwards Lifesciences's revenue?
- Edwards Lifesciences (EW) generated $6.3B in revenue over the trailing twelve months, up 14.1% year over year.
- Is Edwards Lifesciences profitable?
- Edwards Lifesciences reported $1.1B in net income over the trailing twelve months, a 17.4% net margin.
- What are Edwards Lifesciences's profit margins?
- Gross margin is 77.9% and operating margin is 21.4%, with a 17.4% net margin.
- What is Edwards Lifesciences's earnings per share?
- Edwards Lifesciences's diluted EPS over the trailing twelve months is $1.88.
- Where does Edwards Lifesciences's income statement data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
